Dopaminergic treatment strategies for people with Parkinson’s disease in Europe: a retrospective analysis of PRISM trial data

BACKGROUND: Levodopa (LD) is the most effective drug to treat Parkinson’s disease (PD). The recently concluded multinational Parkinson’s Real-World Impact Assessment (PRISM) trial revealed highly variable prescription patterns of LD monotherapy across six European countries. The reasons remain uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Lara, Witzig, Victoria, Schulz, Jörg B., Holtbernd, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570205/
https://www.ncbi.nlm.nih.gov/pubmed/37311949
http://dx.doi.org/10.1007/s10072-023-06888-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570205/
https://www.ncbi.nlm.nih.gov/pubmed/37311949
http://dx.doi.org/10.1007/s10072-023-06888-5

Ejemplares similares